Multi-Center, Prospective, Randomized, Controlled, Trial, Comparing the Safety and Efficacy of ActiGraft Pro™ to Standard of Care in Patients With Chronic Neuropathic Diabetic Foot Ulcers

RedDress Ltd.16 sites in 3 countries119 target enrollmentDecember 20, 2019

ConditionsDiabetic Foot Chronic Ulcer

Overview

Phase: N/A
Intervention: Not specified
Conditions: Diabetic Foot
Sponsor: RedDress Ltd.
Enrollment: 119
Locations: 16
Primary Endpoint: Incidence of complete wound closure by 12 weeks
Status: Completed
Last Updated: last year

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The study is a multi-center, prospective, randomized, controlled, single blinded clinical study consisting of 150 subjects from up to 20 centers.
The subjects are randomized to receive 1 of 2 treatments, either with ActiGraft and standard of care (SOC) or with SOC alone.
The target ulcers are evaluated weekly by the investigator. The subject is treated once a week, to receive weekly applications of the ActiGraft + SOC or SOC until for up to 12 weeks or until the study ulcer has completely healed (i.e., 100% closure as assessed by the Investigator and blinded assessor and confirmed 2 weeks later at the healing confirmation visit (HCV). One additional visit per week is optional for both arms, for the purpose of changing only (1) the secondary dressing in the ActiGraft arm or (2) change the standard of care dressing in the control arm.
Immediately after the study ulcer is confirmed as completely healed, subjects will enter the 12-week Follow-up Phase. During the Follow-Up phase, subjects will be evaluated twice during the first month and then monthly for two additional visits every 4 weeks until the completion of the 12-week Follow-up Phase.

Registry

clinicaltrials.gov

Start Date

December 20, 2019

End Date

April 1, 2024

Last Updated

last year

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

RedDress Ltd.

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Subject is ≥19 years of age and has type 1 or 2 diabetes
•Chronic neuropathic DFU, located distal to the malleolus (excluding ulcers between the toes but including those of the heel) and depth ≤ 5 mm with no exposed capsule, tendon or bone and no tunneling, undermining or sinus tracts (Minor tunneling and undermining will be included).
•Ulcer size between 1 cm2 and 28 cm2 (post-debridement).
•For subjects with potentially multiple eligible DFUs, the largest non-healing wound will be selected.
•Ulcer duration of ≥ 30 days. Time 0 for ulcer duration of ≥ 30 days is defined as the first day of screening (i.e., day -14). Subjects will need to meet all inclusion criteria, including lack of ulcer healing until randomization day.
•Study ulcer separated from other ulcers by at least 1 cm.
•Ulcer or affected limb free of clinical signs of infection.
•Post-debridement, ulcer free of necrotic tissue.
•Adequate circulation to the affected extremity as demonstrated by at least one of the following: (1) Transcutaneous oxygen test (TcPO2) ≥ 30 mm Hg,; (2) Ankle Brachial Index (ABI) between 0.7 and 1.2; (3)Triphasic or biphasic Doppler arterial waveforms at the ankle of affected leg; (4) Toe Brachial Index \> 0.6
•HbA1c ≤ 12.0%

Exclusion Criteria

•Ulcer not of neuropathic diabetic foot pathophysiology (e.g., venous, vasculitic, radiation, rheumatoid, collagen vascular disease, or arterial etiology, or pressure ulcers.).
•Known or suspected ulcer malignancy of the index ulcer.
•Active Charcot of the affected foot
•Presence of underlying osteomyelitis.
•Subject with a proven sepsis established by a blood culture in the past 2 weeks, or confirmed active infection likely to interfere with trial, such as urine tract infection.
•History of alcohol or substance abuse, within the previous 2 months
•Subject has participated in another clinical trial involving a device or a systemically administered investigational study drug or treatment within 30 days of randomization visit.
•Subject is currently receiving (i.e., within the past 30 days) or scheduled to receive a medication or treatment which, in the opinion of the Investigator, is known to interfere with, or affect the rate and quality of, wound healing (e.g., systemic steroids (more than 10mg per day), immunosuppressive therapy, autoimmune disease therapy, cytostatic therapy within the past 12 months, dialysis, radiation therapy to the foot, planned vascular surgery on the study ulcer limb on the 90 days from screening, angioplasty or thrombolysis, chemotherapy).
•Subject has been treated with wound dressings that include growth factors, engineered tissues or skin substitutes (e.g., Regranex®, Dermagraft®, Apligraf®, GraftJacket®, OASIS®, Primatrix®, Matristem®, etc.) within 30 days of randomization or is scheduled to receive during the study.
•Subject has been treated with hyperbaric oxygen within 5 days of screening or is scheduled to receive during the study.

Outcomes

Primary Outcomes

Incidence of complete wound closure by 12 weeks

Time Frame: 12 weeks

Incidence of complete wound closure by 12 weeks using chi square (two-sided; alpha set at .05 level of significance), or Fischer exact test if one group has ≤ 5 completely closed wounds. Analysis will be adjusted using generalized linear modeling (logit function).

Secondary Outcomes

Time to complete wound closure(12 weeks)
Nature, frequency, and severity of adverse events in the intent to treat population(12 weeks)
Percent area reduction (PAR)(4 weeks and 8 weeks)
Number of patients showing a consistence wound closure post healing determination(24 weeks)